Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Conditions:   Solid Tumor, Adult;   FGFR2 Amplification;   FGFR2 Gene Mutation;   FGFR2 Gene Rearrangement;   FGFR2 Gene Translocation;   FGFR2 Gene Activation;   Intrahepatic Cholangiocarcinoma;   Cholangiocarcinoma;   Endometrial Cancer;   Gastric Cancer;   Breast Cancer
Intervention:   Drug: RLY-4008
Sponsor:   Relay Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 20, 2020 / by / in
Comments